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ABSTRACT
Age-related hearing loss (ARHL) -presbycusis - is the most prevalent neurodegenerative disease and number
one communication disorder of our aged population; and affects hundreds of millions of people worldwide. Its
prevalence is close to that of cardiovascular disease and arthritis, and can be a precursor to dementia. The
auditory perceptual dysfunction is well understood, but knowledge of the biological bases of ARHL is still
somewhat lacking. Surprisingly, there are no FDA-approved drugs for treatment. Based on our previous studies
of human subjects, where we discovered relations between serum aldosterone levels and the severity of ARHL,
we treated middle age mice with aldosterone, which normally declines with age in all mammals. We found that
hearing thresholds and suprathreshold responses significantly improved in the aldosterone-treated mice
compared to the non-treatment group. In terms of cellular and molecular mechanisms underlying this
therapeutic effect, additional experiments revealed that spiral ganglion cell survival was significantly improved,
mineralocorticoid receptors were upregulated via post-translational protein modifications, and age-related
intrinsic and extrinsic apoptotic pathways were blocked by the aldosterone therapy. Taken together, these
novel findings pave the way for translational drug development towards the first medication to prevent the
progression of ARHL.

INTRODUCTION
Age-related hearing loss (ARHL – presbycusis) is the
number
one
communication
disorder
and
neurodegenerative disease of our aged population; and
ranks with arthritis and cardiovascular diseases as one
of the top three chronic medical conditions. We have
learned much about the functional declines in auditory
function with age. A loss of hearing sensitivity,
beginning with the high pitches or frequencies, and the
inability to understand speech, particularly in the
presence of background noise, top the list of perceptual
difficulties characteristic of old age [1]. Similar
functional deficits in auditory perception occur in most
aging mammals, including primates and rodents [2-6].
However, despite these advances in understanding the
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perceptual and physiological bases of ARHL, there are
still no FDA-approved drugs on the market to treat the
permanent hearing loss affecting over 40 million
Americans, including presbycusis, and this disappointing situation is exacerbated globally. We are just
reaching the point where our knowledge of the
structural and molecular changes that occur in the inner
ear (cochlea) with age, allow us to start formulating
biomedical interventions to prevent or slow down the
progression of ARHL. For example, it has recently
been shown that knockout mice, deficient in an
antioxidant protein, show accelerated age-linked loss of
inner hair cells, which can be treated with an
antioxidant, N-acetyl-cysteine (NAC) [7].
There are three dominant morphological changes that
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occur in the aging cochlea [8, 9]. i) Sensory
Presbycusis: the loss of sensory hair cells, first outer
hair cells, followed later by inner hair cells; ii)Neural
Presbycusis: declines in the number of spiral ganglion
cells; where the number of ganglion cells typically
decreases up to 25% along the entire cochlear duct
across the lifespan (e.g., [10, 11] and iii) Metabolic
Presbycusis: atrophy of the stria vascularis of the
cochlear lateral wall of scala media. The latter is linked
to dysfunction of the Na-K-ATPase and NKCC1 ion
channel pumps within the stria vascularis. An animal
model, mice treated with ouabain, an inhibitor of Na-KATPase, involves both metabolic and neural
presbycusis. When ouabain is applied to the cochlea it
leads to Na-K-ATPase-associated apoptosis and
degeneration of auditory nerve fibers or spiral ganglion
cells of the cochlea [12]. The preferential loss of the
low-spontaneous group of spiral ganglion neurons and
declines of the endocochlear potential (EP) are related
characteristics of presbycusis [13, 14]. More
specifically, it has been demonstrated that the
maintenance of the EP with its high potassium ion

concentration requires a full complement of NKCC1
and Na-K-ATP channels in the basolateral membrane of
the cochlea’s specialized endolymph organ: the stria
vascularis (SV) and ALD directly regulates protein
expression and activity of NKCC1 channels [84].
But according to other animal model studies [13, 15,
16], the EP declines in the cochlea happen in later
stages of life. Aldosterone (ALD), a steroid hormone
from the mineralocorticoid family, helps determine the
levels of potassium (K+) and sodium (Na+) ions, by
regulating NKCC1 and Na-K-ATPase expression.
Therefore, ALD is a drug candidate to treat ARHL,
since it could delay or reverse stria metabolic
pathogenesis.
Specifically, a noteworthy correlation between ALD
serum levels and ARHL has been observed [17-20]. In
addition, ALD levels decrease with age in many species
including humans and mice [21-27]. As an example, we
previously discovered that higher serum aldosterone
(ALD) levels correlate with better hearing in aged
human subjects [17]. Also, ALD has been shown to

Figure 1. ABR threshold shifts (dB) for treated and untreated (control) subject groups following 60 and 120 days of
treatment. 12 kHz (a), 24 kHz (b), 32 kHz (c) and 36 kHz (d). Mean (±SEM) frequency-specific ABR threshold shifts in the treatment

group (n = 5) on days 60 and 120 compared to the control group (n=5) values, showed improved hearing sensitivity for all four test
frequencies, with the greatest benefit at the higher frequencies. “0” on the ordinate represents the baseline (pre-treatment) ABR
thresholds. So, negative threshold shifts represent improvements in hearing with time in the ALD treatment group, while positive
shifts indicate age-related ABR threshold elevations in the control group. (e) ABR audiogram data upon which 1a – 1d are based.
Top: Very little change in auditory sensitivity occurs in the ALD treated mice. Bottom: The control mice show typical age-related
hearing loss threshold elevations over the 4-month treatment period. Graphs show means (±SEM); solid line is the pre-treatment
baseline ABR audiogram; the dotted line is for 60 days, and the dashed line is for 120 days of treatment. ANOVA: +p<0.05 for 60
days; *p<0.05 for 120 days; **p<0.01 for 120 days, ****p<0.0001 for 120 days.
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influence hearing, with oral administration reversing
autoimmune hearing loss in mice, while spironolactone
(an aldosterone antagonist) blocked this effect [18-20].
In light of these previous findings, in the present
investigation we test the hypothesis that ALD may be
beneficial for the aging auditory system through
mechanisms involving improved hearing, cochlear cell
preservation and mineralocorticoid receptor (MCR)
upregulation. Part of the rationale is that normal
activation of MCRs in neural systems leads to
maintenance of neuronal function and survival (e.g.,
[28]). ALD-MCR-mediated effects are often
independent of agonist ligands, such as in transport
epithelial cells of the renal tubule, but in neuronal
systems, such as hippocampal neurons, it is liganddependent [29, 28, 30, 31]. In sum, spiral ganglion
neurons and SV cells could be regulated by ALD to
modulate cell survival. The present article reports a
series of experiments that investigate how ALD is
associated with cochlear presbycusis and its possible

roles in delaying or preventing age-related hearing
impairment. These studies not only provide novel
insights into the molecular mechanisms underlying the
regulation of spiral ganglion and SV cell survival with
age, but could also lead to the development of novel
therapeutic strategies for the prevention and treatment
of ARHL, affecting many millions of people
worldwide.

RESULTS
Aldosterone treatments prevent age-related hearing
threshold elevations and improve hair cell responses
First, standard hearing measurements were made to test
the hypothesis that ALD may be beneficial for
preventing or delaying age changes in the auditory
system. The ALD pellet implantation was started at age
17 months, and lasted for 4 months. Long-term ALD
treatment effects on peripheral hearing were assessed in

Figure 2. ABR Peak 1 amplitude changes (µV) as a function of sound intensity, for treated and untreated
(control) subject groups, following 60 and 120 days of treatment. 12 kHz (a), 24 kHz (b), 32 kHz (c) and 36 kHz (d).

Note that the ALD treatment ABR levels tend to be above the control levels at 60 and 120 days of treatment, especially at the
higher intensities, and for 12 and 24 kHz. Also, the control levels at the 120 day time point tend to be the lowest of all, due to
the normal progression of age-related hearing loss. Quantification of these relative improvements in the ALD treatment
groups for 80 dB SPL are given in the next Figure. Error bars are SEM.
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mice by computing the ABR threshold shifts at 12, 24,
32 and 36 kHz and suprathreshold sound coding was
measured with ABR peak amplitude intensity functions.
Threshold improvements due to the ALD treatments
were discovered at all frequencies with statistically
significant improvements found when comparing the
treated group to the non-treated control group (Figs. 1ae). These data indicate that the maximum therapeutic
effect is in the cochlear base, where ARHL typically
exerts its maximal effects, with smaller improvements
in the low frequency, apical region. In addition, ABR
peak I amplitudes were found to be reduced at high
intensities in the aging control group, but after longterm ALD treatment amplitudes were significantly
increased, as displayed in Figures 2 and 3. Specifically,
the increase in P1 amplitude from baseline controls is
shown as a function of the intensity of the tone burst
stimulus for 12, 24, 32 and 36 kHz, panels 2a-d,

respectively. Improvements in threshold and
suprathreshold benefits of the ALD were manifested at
60 days and became more prominent at 120 days of
treatment, as shown for 80 dB in Figure 3 for all test
frequencies, i.e., the ALD-treated ABR suprathreshold
responses are higher than the controls. Also note that
the treatments actually improved the ABR thresholds
relative to the baseline thresholds that were measured
just prior to the beginning of the treatments (baseline =
0 for the Figs. 1a-d ordinates; a negative shift indicates
threshold improvements over the course of the
treatments).
Consistent with Schuknecht’s classification scheme
presented above ([8, 9]), ARHL in the CBA/CaJ mouse
involves both hair cell and spiral ganglion neuron loss.
Therefore, we made initial observations about the status
of the outer hair cell system, by measuring distortion

Figure 3. ABR Peak 1 amplitude changes (µV) at 80 dB SPL, for treated and untreated (control) subject groups,
following 60 and 120 days of treatment. 12 kHz (a), 24 kHz (b), 32 kHz (c) and 36 kHz (d). Box plots (median, 1st & 3rd

quartiles, whiskers: minimum & maximum) of frequency-specific ABR P1 amplitude changes in the treatment group (n = 5) on
days 60 and 120 compared to the control group (n=5) values, showed improved hearing, i.e., increased ABR amplitudes, for all
four test frequencies, with the greater benefits at the higher intensities. “0” on the ordinate represents the baseline (pretreatment) ABR amplitude levels. So, positive shifts represent increased excitatory drive with time in the ALD treatment group,
while negative shifts indicate age-related ABR level decreases in the control group. ANOVA: *p<0.05; error bars are SEM.
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product otoacoustic emissions (DPOAEs) before and
after ALD therapy. The results indicated an
improvement in DPOAE thresholds in 21 month old
mice with 60 day ALD treatments (Fig. 4). Based on
these data, it appears that extended ALD treatments will
significantly retard certain aspects of the aging process
on hair cell loss; a finding worthy of more extensive
investigation in subsequent studies.
Serum aldosterone levels increased into the normal
range in old mice with aldosterone therapy
Our preliminary findings in middle age CBA/CaJ mice
provided an appropriate dosage for the longitudinal
studies reported here [32]. In untreated aging mice, agerelated declines of nearly 50% in serum ALD levels
occur as compared to young adult mice (details

presented in Fig. 5). However following treatments,
serum ALD levels rose to near the normal range, very
close to that of the young adult comparison group (Fig.
5). As we report in our companion article [33], ALD
treatments did not elevate blood pressure; i.e., mean
systolic (~120 mm Hg) and diastolic (~85 mm Hg)
pressures remained stable relative to the baseline, and
over the treatment periods of 60 and 120 days in both
the control and treated groups. These results indicate
that long-term ALD treatment does not induce a
potential negative side effect, using the therapeutic
dosing regimen of the present study.
Aldosterone rescues age-related spiral ganglion cell
loss
Interactions between improvements in hearing due to

Figure 4. DPOAE amplitudes and thresholds for treated and untreated (control) subject groups, following 60 and 120
days of treatment. (a) Amplitudes for the ALD (top) and Control (bottom) groups are similar to each other, and do not change

systematically during the treatment period. (b) The DPOAE thresholds show improvement at the higher frequencies for the ALD
treatment group at 60 days (top), but not for the Control group (bottom). Graphs show means (±SEM). ANOVA: *p<0.05; **p<0.01,
***p<0.001, ****p<0.0001.
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(SGN) density and ABR threshold shifts following 120
days of treatment with ALD: for 24 kHz vs upper basal
SGN, r2 = 0.48, p = 0.027 (Fig. 6c, top); and for 36 kHz
vs lower basal SGN, r2 = 0.72, p=0.002 (Fig. 6c,
bottom). The rescue of SGNs provides anatomical
confirmation that ALD has a protective effect on SGN
survival with age and provides a basis for the
maintenance of high frequency hearing ability.
Mineralocorticoid receptors are expressed in the
cochlea
Figure 5. The serum aldosterone levels from young
adult and middle age CBA/CaJ mice with or without the
aldosterone treatment, 0.0016 mg/day continuous
release, subcutaneous pellet through 120 days. The
systemic aldosterone treatment restored serum levels to near
the normal range for young adults. Graphs show means
(±SEM). ANOVA: ****p<0.0001.

the ALD treatments and spiral ganglion neuron density
were explored. Specifically, the spiral ganglion cell
numbers in middle-age treated and control mice were
compared to that of the untreated young adults. To
accomplish this, cochlear cross sections were subjected
to H&E staining and spiral ganglion cell counts were
made for each cochlear turn (Fig. 6a). Mean cell
counts/10,000 μm2 significantly decreased in the
untreated middle-age mice (Figs. 6b), compared to the
young adult mice. However, following long-term ALD
treatment there was a noteworthy increase in the
number of surviving spiral ganglion neurons, relative to
age-matched controls, indicating a therapeutic effect at
the level of the modiolus.
Functional hearing preservation with aldosterone
correlates with spiral ganglion cell rescue
In order to test for co-localization of spiral ganglion
neuron rescue with frequency-specific hearing
improvements following ALD treatments, the murine
cochlear place-frequency map derived by Muller was
utilized [34]. Müller and colleagues determined the
cochlear location of physiologically characterized
auditory nerve fibers along the cochlear partition and
then mapped the location with best frequency [34, 35].
For example, a best frequency of 19.6 kHz was
localized to a position 50.2% from the cochlear base,
while 40.5 kHz is 18% from the basal end of the
cochlea. In the present study, histological confirmation
of the location of spiral ganglion neurons was correlated
to ABR thresholds data. Specifically, relations between
spiral ganglion neuron loss and ABR threshold shifts at
24 and 36 kHz were examined, and the results revealed
a positive correlation between spiral ganglion neuron
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Aldosterone is known to exert its physiological effects
through the activation of mineralocorticoid receptors
(MCRs). In general, MCRs are involved in the
maintenance of cellular and structural integrity of
neurons required for normal cognition, behavior and
endocrine control [36]. Furthermore, MCRs are
important for neuronal survival in the rat hippocampus,
and increased survival of rat primary cortical neurons in
response to mild stressors [28]. MCRs also improve
survival of hippocampus neurons after transient global
ischemia, and play regulatory roles in many other
tissues [37, 38]. We hypothesized that like central
nervous system neurons, SGNs would also be under the
influence of the aldosterone-MCR axis. To test this, the
expression patterns of MCRs in SGN cell bodies were
examined. As a positive control RNA from mouse heart
and liver were utilized, as MCRs are known to be
abundant in cardiac and liver tissue [39-41]. A sample
from the mouse heart without reverse transcription was
used as negative control condition. Moderate MCR gene
(Fig. 7, top) and protein (Fig. 7, bottom) expression was
observed in the SGNs of young adults, and in stria
vascularis cell bodies (not shown). More intense
staining was observed in other cochlear structures such
as the tectorial membrane.
Aldosterone reverses the down-regulation of MCRs
with age by blocking posttranslational modifications
MCR-mediated effects are largely independent of
agonist ligands in transport epithelia such as the renal
tubules, however this is not the case in neuronal
systems, such as the brain, including the hippocampus,
where modulation of the presence of MCR is ligand
dependent [29, 30, 31]. As shown in Figure 8a, mRNA
expression of MCRs in spiral ganglion neurons was
detected, but there was no difference in the gene
expression levels among all the subject groups. In
contrast, both proteomics methodologies employed
(immunohistochemistry, western blot), revealed that the
MCR protein expression is down-regulated in spiral
ganglion neurons of middle aged mice compared to
young adults (Figs. 8b, 8c). However, following 4
months of ALD treatment a 2-fold up-regulation of
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MCR expression occurred. These results indicate that
age-related down-regulation of MCRs in spiral ganglion
cells involves a post-transcriptional modification that
can be prevented by ALD hormone therapy initiated in
middle age.
Molecular mechanisms
ganglion neuron death

for

age-linked

spiral

One known mechanism by which MCRs can influence
neuron survival in the brain is by inhibiting apoptosis
[42]. In addition, we have previously identified agelinked upregulation of apoptotic pathways in the

CBA/CaJ cochlea [43]. The signaling cascades inducing
apoptosis in mammalian cells can be divided into two
pathways: either mitochondrial (intrinsic) or death
receptor (extrinsic) [44-46]. However, the extent to
which apoptosis is a key mechanism for age-related
spiral ganglion cell loss is not known. For instance, a
previous investigation found no effects of Bax-/- or Bcl2 over-expression on age-related loss of spiral ganglion
neurons [47]. Based upon this study, and our previous
work on cochlear apoptosis in CBA/CaJ mice [43], we
further investigated the role that apoptotic pathways
play in age-related spiral ganglion neuron loss.
Pathways involved that may be independent of Bax/Bcl-

Figure 6. Hematoxylin/eosin (H&E) staining patterns in the cochlea reveal spiral ganglion neuron (SGN) loss with age,
and rescue with aldosterone hormone treatments. (a) Cross section of the complete CBA mouse cochlea showing all turns:

Section-thickness is 5 µm, Magnification: 2.5 X 1.6. All cochlear turns are distinguishable as: upper apical, upper basal, lower apical
and lower basal. The cell number measurements of SGNs included all turns: (b) SGN cell count densities were measured by light
microscopy for the young adult (left panel) and middle-aged mice with (right panel) and without (middle panel) aldosterone
treatments; Magnification: 20 X 1.6. Right panels show bar graphs representing the SGN cell density. Mean ±SEM for each subject
group. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. (c) Statistically significant correlations between SGN density and 24 and 36
kHz ABR threshold shifts indicate that a reduction in the number of SGNs are associated with poorer hearing (higher ABR thresholds).
Open points are for ALD treated animals, and filled points are for the controls who are undergoing normal age-related hearing loss.
According to the physiological place-frequency map of the mouse cochlea (see text), 24 and 36 kHz are located at upper and lower
basal turns of the cochlea, which correspond to the cochlear locations with the most cell density loss with age in CBA/CaJ mice.
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reactions), activated two caspase-8 fragments, p18 and
p43, in spiral ganglion neurons of middle age mice
compared to the young adult group. In addition,
following the 4 months of ALD treatment Caspase-3
expression levels were significantly reduced, and
simultaneously the induction of cleaved caspase-3
disappeared (Fig. 9b, Western blot). Also, the declines
of Bcl-2 with age were reversed, and the levels of
activated Bax and caspase-8 were decreased with the
ALD treatment (Fig. 9c). So together, these data
indicate that the extrinsic and intrinsic apoptotic
pathways are upregulated with age in spiral ganglion
neurons, and ALD can be a double-edged intervention
to block age-related apoptosis. These studies support the
hypothesis that age-related cochlear neuron loss
involves both extrinsic and intrinsic apoptotic pathways.

Figure 7. Mineralocorticoid receptor (MCR) expression
and distribution in the cochlea of the young adult (3
mon) CBA/CaJ mouse. (a) Multiplex RT-PCR was performed

as described in the text. This experiment includes the absence
of reverse transcription (control lane -RT). The mRNA
expression of MCRs in tissue from heart (H), muscle (M) and
spiral ganglion neurons (SG), where the product of RT-PCR is
about 245 bp. -RT- reverse transcription without primers (as
the negative control). L-Ladder: DNA molecular weight
markers. (b) The protein expression of MCRs in SG was
detected using immunohistochemistry staining (brown color,
MCR+). A portion of the limbus is shown as a cochlear region
not displaying significant MCR staining (MCR-).

2 pathways [46], are presented in Figure 9a. The
intrinsic and extrinsic pathways, both at the end point of
the execution phase, are often considered key
components of the final apoptotic pathway. It is the
activation of the execution caspases that begins this
terminal phase of apoptosis. Execution caspases activate
cytoplasmic endonucleases, which degrade nuclear
material, and involve proteases that break down nuclear
and cytoskeletal proteins. Caspase-3 is often considered
to be the most important of the executioner caspases
and is activated by any of the initiator caspases [48, 46].
We assayed the expression of Caspase-3 in spiral
ganglion neurons to determine its involvement in
ARHL. As shown in Figure 9b, Caspase-3 expression
increased in middle-age spiral ganglion neurons
compared to young adults, and the induction of cleaved
caspase-3, which is the activated form of caspase-3, was
also observed (Fig. 9b). Relevant to the activation of
either intrinsic or extrinsic pathways, the apoptotic
intrinsic inducer Bax was found to be upregulated, and
the survivor factor Bcl-2 (likely involving inhibition of
mitochondrial cytochrome c release) was downregulated with aging in spiral ganglion neurons (Fig.
9c). These data suggest that the apoptotic intrinsic
pathway is activated in cochlear aging. In addition,
extrinsic factor Caspase-8 (a hallmark of apoptotic
extrinsic pathways such as caspase-1, 3, 6, 7 chain
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Additionally, apoptotic DNA fragmentation is a key
feature of apoptosis, characterized by the activation of
endogenous endonucleases with subsequent cleavage of
chromatin DNA into internucleosomal fragments of
roughly 180 base pairs (bp) and multiples thereof. DNA
fragmentation can be detected via DNA laddering and
the TUNEL assay. However, nucleosomal ladders have
only been clearly demonstrated when vast numbers of
cells die synchronously, so asynchronous cell death
with subtle DNA fragmentation cannot be routinely
detected by DNA fragmentation assays [49]. Therefore,
we used a highly sensitive method, ligation-mediated
polymerase chain reactions (LMPCR), to amplify the
nucleosomal ladder of SGNs from young and middleaged mice [49, 50, 51, 52-55]. Typically, DNA
fragments have 5'-phosphorylated blunt ends, which can
be ligated to dephosphorylated adaptors composed of a
12-mer and a 27-mer. When the mixture of ligated DNA
fragments is heated, the 12-mer is released. Next, the 5'
protruding ends are filled in by a thermostable DNA
polymerase. The 27-mer then serves as a primer in a
PCR in which the fragments with adaptors on both ends
are exponentially amplified. The resulting nucleosomal
ladder can be easily visualized on an agarose/EtBr gel.
The observed increase in apoptosis in aged spiral
ganglion neurons was demonstrated by the elevated
levels of cleaved genomic DNA by formation of a DNA
ladder (Fig 9c), but ALD treatment for 4 months
inhibits the aging induced DNA fragmentation ladder in
spiral ganglion neurons

DISCUSSION
Consistent with the success of the therapeutic
intervention administered to middle age animals to slow
down the progression of ARHL in the present report,
there is growing evidence that key aspects of ARHL
emerge in middle age. For example, the auditory
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efferent feedback system, known as the medial
olivocochlear bundle, arises from the superior olivary
complex of the brainstem and provides efferent control
to the cochlear outer hair cells, providing a gain control
mechanism for regulating hearing sensitivity in the
presence of suprathreshold stimuli and background
noise conditions [56, 57]. We previously discovered in
middle-aged humans [58] and middle-aged mice [5961], that this feedback loop starts to show significant
functional declines. In addition, prevailing evidence
indicates that auditory spectral and temporal processing
deficits start to manifest themselves in middle age
humans [62-64], and in animal models starting in

middle age [65, 66]. Additional investigations, across
the lifespan of CBA/CaJ mice, including young adult
(up to 10 mon), middle age (10-20 mon) and old age
(20- 30 mon) [67, 68], provide additional instances of
relevant auditory functional deficits that start in middleaged mice, including elevations in ABR thresholds,
especially at the higher frequencies.
There is also evidence to support possible roles of
apoptosis in the aging cochlea, as has come from reports
of the association between aging changes in apoptotic
gene expression [43] and alterations in the expression of
apoptosis-related proteins [69, 70]. For example,

Figure 8. MCR presence in spiral ganglion neurons from young adult (3 mon), and aged (21 mon) control mice and
those which were treated aldosterone (ALD) from 17 months up to 21 month. (a) mRNA gene expression of MCRs in young

adult, aged mice and aged mice with ALD treatment were all of similar magnitudes. 3 mon: Modiolar samples from young adult mice,
21 mon: Modiolar samples from aged mice. L-Ladder: DNA molecular weight. (b) The MCR protein expression level was determined
by densitometry analysis (MetaMorph Image Analysis System) of immunocytochemistry sections; upper panels show representative
sections for the MCR antibody staining. The insets in the upper panels represent a typical MCR-DAB stained spiral ganglion neuron.
The lower panel presents a bar graph summarizing the relative densities from densitometry measurements: Mean ± SEM for each
group. (c) MCR protein expression in spiral ganglion neurons shown by western blots of modiolar tissue samples. The expression level
is reported relative to the expression of beta-actin as the loading control. For both measures of protein expression (b and c), the ALD
treatments helped rescue the age-related declines in MCR protein expression. Statistical significance: *p< 0.05, **p<0.01,
***p<0.005, ****p<0.001.
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investigation of a role for apoptosis in hair cell and
SGN loss with age has occurred using the terminal
deoxynucleotidyl transferase-mediated dUTP-biotin
nick end-labeling (TUNEL) method, and the presence
of DNA fragmentation in hair cells and SGNs during
aging has been found [71-73]. However, it is known
that TUNEL is not quite specific for apoptotic cells
even though it is a very popular method to detect
apoptosis, as nuclear fragments from necrotic or
autolytic cells may also be TUNEL-positive. The
occurrence of false positive staining has been noticed

for several conditions such as inappropriate fixation and
unmasking after formalin fixation and paraffin
embedding through protease addition [74-76]. More
recently, the internucleosomal DNA cleavage pattern
has been demonstrated as a specific feature of
apoptosis, and has become a recognized marker of
programmed cell death. However, in conditions in
which only a small percentage of cells are apoptotic, or
in which apoptosis is occurring asynchronously,
genomic DNA ladders may appear as a smear and not
be definitive. So, the ligation-mediated PCR is an

Figure 9. Apoptotic biomarker expression levels in modiolar tissue samples from young adult (2-3 mon), middleaged (20-21 mon) ALD-treated and untreated CBA/CaJ mice. Panel (a) shows the key molecules (Bcl-2, Bax, caspase 3 & 8)

for the apoptotic pathways being investigated. (b) Cleaved caspase-3 protein expression is elevated in middle age controls, but
reduced in ALD-treated mice. Since caspase-3 is an executor of apoptosis and a common factor of the intrinsic and extrinsic
pathways, its upregulation can induce apoptosis. Note: the antibody utilized here also recognizes the cleaved caspase-3 to a
lesser degree. Statistical differences are relative to the young adult levels. (c) To further assess age-related changes in the
apoptotic pathways, the extrinsic factor, caspase-8, and intrinsic factors, Bcl-2 and Bax, were examined using western blots (WB).
All three biomarkers were activated as shown: caspase-8 cleavages including p43 and p18 were enhanced in the middle age mice
compared to the young adults, but reduced in ALD-treated mice. Bax was increased, but Bcl-2 was decreased with aging in SGNs,
and ALD treatment inhibited the age-related changes of both molecules. Lastly, the DNA ladder detected in aging SGNs, but ALD
treatment prevented the genomic DNA to be digested by endonucleases, L-Ladder: DNA molecular weight. *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001.

www.aging-us.com

2090

AGING (Albany NY)

option to amplify the nucleosomal ladder, increasing the
visualization. Figure 10 summarizes the molecular
cascade in which aging promotes the onset of apoptosis
in SGNs, including both intrinsic (Bcl-2, Bax) and
extrinsic (Caspases-dependent) pathways. However, the
age-related involvement of apoptotic pathways in SGN
cell loss in the aged cochlea is still not completely
understood. For example, loss of hair cells and SGNs is
still found in young adult mice lacking caspase-3, a key
downstream caspase in the apoptotic cascade. So, it is
likely that activated caspase-3 may be sufficient but not
essential for the death of hair cells and SGNs [77]. For
example, using both Bax knockout (Bax−/−) and Bcl-2
over-expressing mice, previous investigators failed to
find any significant difference in age-related loss of hair
cells and SGNs between controls and transgenic mice
[47]. Taken together, the results of the present report
and previous studies suggest that age-related hearing
loss does not occur through an apoptotic pathway
involving key members of the Bcl-2 family. However, it
is likely that aging initiates apoptosis processing in an
inner loop network, so inhibiting several key molecules,
but not all apoptotic pathways. According to the
findings of the present report, ALD interferes with the
ageing process involving several molecules, such as
Bcl-2 induction, and Bax and caspase pathway
inhibition. Lastly, since mitochondrial activity is
involved in these apoptotic pathways (Fig. 10), changes
in oxidative stress and their therapeutic regulation may
play a role here in modulating age-related hearing
conditions [78]. In sum, these findings suggest that
developing a biomedical intervention to be administered
in middle age, would be an optimal time point to
prevent or decrease salient features of ARHL.
In closing, the auditory system provides a unique
window into the neurobiological changes that occur in
the aging nervous system. Hearing and auditory
perceptual capabilities can be tested quickly and
quantitatively, so that correlations between sensory
perception and anatomical and molecular biomarkers
can be compared quantitatively, as was accomplished in
the current investigation. For example, in the present
study we showed that ALD treatments over a 4-month
period could help preserve hearing in aging mice, and
identified several key biomarkers, including
mineralocorticoid receptors on SGNs, which are related
to both apoptotic intrinsic and extrinsic pathways. So
the present investigation is an essential pre-clinical step
forward. Verification of these findings in another
mammalian species, and exploration of the possible
therapeutic effects on additional biological mechanisms
of ARHL, to justify trials in humans will be additional
necessary steps to move towards FDA clinical trials.
Translationally, it may be that ALD combined with
other critical compounds could be given systemically

www.aging-us.com

2091

Figure 10. Schematic of the potential molecular
pathways which illustrate the main findings of the
present investigation, suggesting that ALD interferes
with apoptotic pathways for aging in spiral ganglion
neurons. Aging processes triggers Bcl-2 inhibition and Bax

activation, which are key factors in intrinsic pathways, and
promotes the caspase-dependent extrinsic pathway. Aldosterone, through the activation of cochlear mineralocorticoid
receptors, blocks apoptotic processing induced by aging, i.e.,
Bcl-2 is increased and Bax is decreased to inhibit the intrinsic
apoptosis induced by aging, Caspase-dependent pathways are
also inhibited.

(orally, time-release skin patch), if there are no side
effects, or have beneficial systemic effects for an aging
mammal. Alternatively, if side effects are detrimental
(which was not the case in the current study, e.g., stable
blood pressure throughout the treatment period), a
medicine to improve hearing in the elderly could be
given locally to the inner ear via microsystem delivery
techniques that we are currently developing [79-82], or
via transtympanic injections into the middle ear near the
round window, perhaps using nanoparticles as drug
carrying vehicles.
CONCLUSION
The findings of the current report indicate that ALD, a
naturally occurring hormone that declines with age,
when prescribed in middle age, can prevent or slow
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down some of the key aspects of presbycusis in aging
mice. Our new results point towards possible cellular
and molecular mechanisms for this therapeutic effect:
Upregulation of mineralocorticoid receptors via
reduction of post-translational protein modifications,
preservation of hair cells and spiral ganglion cells, and
partial blocking of apoptotic and cell death pathways.
These animal model findings pave the way for
translational medicine development of an FDA
approved drug to treat presbycusis, which affects
hundreds of millions of people worldwide. It is likely
that an approved drug to treat ARHL will be a cocktail
of two or more therapeutic agents, and based upon the
discoveries in the current report, ALD will be one of
those key compounds.
MATERIALS AND METHODS

tubes to the opening of the external ear canal. The
response was amplified (10,000 X), filtered (100 Hz–3
kHz), and averaged using the BioSig (TDT, Gainesville,
FL) data acquisition system. A total of 200 responses
were averaged (with stimulus polarity alternated), using
an ‘artifact reject’ algorithm, whereby response
waveforms were discarded when peak-to-peak
amplitude exceeded 7 μV, to prevent contamination by
muscle activity. Intensity was varied in 5 dB steps
starting at 80 dB and decreasing to at least 20 dB below
threshold for a specific test frequency. Each intensity
was replicated and threshold was defined as the lowest
intensity at which a response was replicated, as
determined by two experimenters blind to the
experimental condition. The recording sessions
occurred every 2 months after the initial evaluation
(baseline) for a period of 4 months.

Subjects

Distortion product otoacoustic emissions (DPOAEs)

Fifteen CBA/CaJ young adult (2-3 mon) and middleaged mice (16-17 mon) served as subjects. Original
breeding pairs were purchased from Jackson Labs (Bar
Harbor, ME), and used to provide an in-house source of
subjects that were housed and maintained in a standard
husbandry facility of the University of South Florida
Vivarium. All procedures were compliant with the
University of South Florida IACUC protocols and all
federal animal welfare regulations, including the NIH
Guide for the Care and Use of Laboratory Animals.

Ipsilateral acoustic stimulation and simultaneous
measurement of DPOAEs were accomplished with the
Tucker Davis Tech. (TDT) BioSig III system. Stimuli
were digitally synthesized at 200 kHz using SigGen
software applications with the ratio of frequency 2 (F2)
to frequency 1 (F1) constant at 1.25; L1 was equal to 65
dB sound pressure level (SPL) and L2 was equal to 50
dB SPL as calibrated in a 0.1-mL coupler simulating the
mouse ear canal. After synthesis, F1, F2, were each
passed through an RP2.1 D/A converter to PA5
programmable attenuators. Following attenuation, the
signals went to ED1 speaker drivers which fed into the
EC1 electrostatic loudspeakers coupled to the ear canal
through short, flexible tubes with rigid plastic tapering
tips. For DPOAE measurements, resultant ear canal
sound pressure was recorded with an ER10B+ lownoise microphone and probe (Etymotic) housed in the
same coupler as the F1 and F2 speakers. The output of
the ER10B+ amplifier was put into an MA3 microphone
amplifier, whose output went to an RP2.1 A/D
converter for sampling at 200 kHz. A fast Fourier
transform (FFT) was performed with TDT BioSig
software on the resultant waveform. The magnitude of
F1, F2, the 2f1-f2 distortion product, and the noise floor
of the frequency bins surrounding the 2f1-f2
components were measured from the FFT. The
procedure was repeated for geometric mean frequencies
ranging from 5.6 to 44.8 kHz (eight frequencies per
octave) to adequately assess the neuroethologically
functional range of mouse hearing.

Hearing measurements
The ABR and DPOAE testing procedures were similar
to our previous reports [59, 61, 68].
Auditory brainstem response (ABR) procedures
Middle-aged mice were divided into two groups:
treatment (N=5) and control (N=5), and had clearly
visualized, healthy tympanic membranes. Prior to
recording the auditory brainstem response (ABR) mice
were anesthetized with a mixture of ketamine/xylazine
(120 and 10 mg/kg body weight, respectively, IP
injection). Briefly, ABR sessions were carried out in a
soundproof acoustic chamber (IAC lined with Sonex),
with body temperature maintained at 37°C with a
heating pad. Prior to recording, the stimulus probe was
placed near the tympanic membrane with the aid of an
operating microscope. Needle electrodes were inserted
at the vertex (non-inverted) and in the muscle posterior
to the left pinna (inverted), with a ground inserted under
the contralateral pinna. ABR waveforms were evoked
with 5 msec tone pips (0.5- msec rise-fall times) with a
cos2 onset envelope, delivered at 21/sec though
electrostatic speakers (TDT EC1) connected by 4 cm
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Mice were anesthetized with a mixture of ketamine and
xylazine (120 and 10 mg/kg body weight, respectively)
by intraperitoneal injection before all experimental
sessions. All recording sessions were completed in a
soundproof acoustic chamber (lined with Sonex) with
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body temperature maintained with a heating pad. Before
recording, the operating microscope (Zeiss) was used to
place the stimulus probe and microphone in the test ear
close to the tympanic membrane. The recording session
duration was limited by depth of anesthesia, and lasted
approximately 1 hour per animal.
Aldosterone hormone treatment implantation
After baseline ABR recording at 16-17 months of age,
while still fully anesthetized, mice were assigned
randomly to the treatment or control groups; the
treatment group received implantation injection of a
custom d-aldosterone pellet: 0.0016 mg/day, 120-day
release (Innovative Research of America, Sarasota, FL),
and the control group received the saline placebo, both
placements were subcutaneous, just behind the
shoulder. Blood Pressure Measurements: As a measure
of cardiovascular health, a group of young adult (N=5)
CBA/CaJ mice, and the middle-aged mice described
above were placed in a restraining tube to acclimate
them to having their blood pressure (BP) measured, by
placing them in a holder for 15 min for 3 consecutive
days prior to the actual BP measurements (Kent
Scientific CODA™ tail-cuff system). The animal was
either placed in the holder by picking up the tail, or the
animal entered freely. The rear hatch to the holder was
carefully secured, and care taken to avoid pinching the
tail or any other body parts while securing the rear
hatch. The mouse was allowed to rest at least 5-minutes
to acclimate to the holder.
Serum collection and anatomical tissue preparation
After 4 mon of ALD treatments, the middle-aged and
young adult mice were exsanguinated via cardiac vessel
perfusion, with Euthasol® (0.22ml/kg). A thoracotomy
was performed to gain access to the heart and the
cardiac vessel was punctured by an 18G sterile
hypodermic needle. Blood was allowed to free-flow
from the puncture site and collected with a sterile
Pasteur pipette, then transferred to an Eppendorf tube in
a 37oC water bath for 30 min, centrifuged 2000 rpm for
25 min, and then the serum was taken off and stored at 80oC. The mouse was then decapitated, and the
cochleae were quickly removed from the temporal bone
and transferred into ice-cold DPBS (HyClone Lab Inc.,
Logan, UT) on ice to dissect the modiolus from one of
the cochlea using a Zeiss stereomicroscope; and then it
was placed into an Eppendorf tube in dry ice and
transferred into -80oC in preparation for RT-PCR and
Western blots.
Immunohistochemistry
The other cochlea was placed in a glass vial with 10 ml
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fresh 4% paraformaldehyde (Thermo Scientific,
Rockford, IL) in PBS (0.1 M, pH 7.6) overnight at 4oC.
After fixation, the cochleae were washed 3 X 10 min in
PBS and then decalcified in 20 ml 10% EDTA
(ethylenediaminetetraacetic acid, Fisher Scientific,
Pittsburgh, PA) in PBS at 4oC; the cochleae were
checked daily until decalcification was complete
(approximately 1 week). Next, they were washed 3 X
10 min in PBS, transferred into 10% and 20% sucrose
(Acros, Geel, Belgium) in PBS for 2 hours each, then
kept in 30% sucrose in PBS for overnight at 4oC until
sinking. The cochleae were embedded into degassed
OCT (Tissue-Tek, Torrance, CA) overnight at 4oC,
orientated into the cryomold (Tissue-Tek) with OCT
degassed for 1 hr, and then frozen at -80oC.
Cryosectioning was performed at 5μm/section, and
sections were mounted on glass slides.
Hematoxylin and Eosin (H&E) Staining
Cochlear slides were washed in dH2O for 1 min, and
then stained for 5 min with the BBC Histo•Perfect™
H&E Stain kit (BBC Biochemical, Mt. Vernon, WA).
Slides were rinsed with dH2O for 1 min, differentiated
by BBC Acid wash for 1 min, and rinsed with dH2O for
1 min; then placed into BBC Blueing solution for 30
sec, and rinsed by dH2O for 1 min. Next, the slides went
into 70% alcohol for 30 sec, stained with BBC Special
Eosin II for 1 min, dehydrated with BBC S2*Histo 5 X
20 sec, and cleared in xylene and coverslipped using a
permanent mounting media (Fisher Scientific,
Pittsburgh, PA). Semi-automated cell counts were made
using the MetaMorph imaging system with a Leica
DMR microscope, using procedures similar to our
previous investigations of the mouse aging auditory
system [61, 68, 83].
Receptor protein expression
immunohistochemistry

measured

with

Mineralocorticoid Receptor (MCR): Cochlear section
slides were washed in TBS twice for 5 min. They were
then incubated for 10 min at room temperature in 3%
H2O2, diluted in methanol, and washed with TBS for 2
X 5 min. Each section was treated with 100-400 μl
blocking solution (0.3% triton- X 100 and 5% normal
goat serum in TBS) for 1 hr at room temperature. Then
removed from the blocking solution, with the addition
of 100-400 μl anti-MCR (SC-25709, Santa Cruz
Biotechnology, Dallas, TX) 1:25 diluted in blocking
solution. Next, incubated overnight at 4oC. In the
morning, the slides were washed in TBS 3 X 5 min,
then Covered with 1-3 drops of signal stain boost IHC
detection reagent (HRP, Rabbit, Cell Signaling,
Danvers, MA) and incubated in a humidified chamber
for 30 min at room temperature. Then, 3 X 5 min
washes with TBS. Then 100-400 μl DAB was placed on
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each slide for intensification, then the slides were
immersed in dH2O, and washed 2 X 5 min, followed by
dehydration and coverslipping.
ELISA for measuring serum aldosterone levels
50 μl serum samples were processed using an
aldosterone ELISA kit (#1875, Alpha Diagnostic Int.,
San Antonio, TX) according to the manufacturers’
protocol.
An
absorbance
microplate
reader
(ELx800TM) and microplate data collection & analysis
software (Gen5TM, BioTek, Winooski, VT) were used
for data collection, with data reported as pg/ml. The
expected young adult range for mice is 25-315 pg/ml.
Gene expression - RT-PCR
Semi-quantitative RT-PCR analysis was performed as
previously described [84, 85]. Briefly, total RNA was
extracted using the RNAeasy Mini Kit (Qiagen,
Valencia, CA). Tissue and cells were vortexed for 1 min
to shear genomic DNA before loading onto the RNeasy
mini columns, and then eluted in a minimum volume of
30 ml and a maximum volume of 2 x 50 ml RNAasefree water. RNA obtained with this procedure was
essentially free of genomic DNA. 10 ng of RNA was
reverse transcribed and cDNA was subjected to PCR
amplification. A quantitative reverse-transcription
polymerase chain reaction (qRT-PCR) was performed
using the Enhanced Avian HS RT-PCR-100 Kit
(HSRT20, Sigma, St. Louis, MO). The reverse
transcript (RT) reaction took place at 45°C for 50 min.
The competition between primer sets was excluded by
adjusting the reaction condition. Then the RT products
went to PCR amplification directly. A first cycle of 10
min at 95°C, 45 sec at 65°C and 1 min at 72°C was
followed by 45 sec at 95°C, 45 sec at 65°C and 1 min at
72°C for 25 cycles (see below). The conditions were
chosen so that none of the RNAs analyzed reached a
plateau at the end of the amplification protocol, i.e. they
were in the exponential phase of amplification. Each set
of reactions always included a no-sample negative
control. We also performed a negative control
containing RNA instead of cDNA to rule out genomic
DNA contamination. The PCR products were analyzed
on agarose gels stained with Gel Red Nucleic Acid
Stain (Biotium, Hayward, CA).
Nucleosomal ladders detection
Nucleosomal ladders were revealed by a ligationmediated polymerase chain reaction (LMPCR).
Genomic DNA was isolated using GenElute TM
Mammalian Genomic DNA Miniprep Kit (Sigma, St.
Louis, MO) according to the procedure described by
their standard protocol. A 0.5 µg/sample of the digested
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DNA template was used. The first step is the ligation of
dephosphorylated adaptors (120-mer and 27-mer,
provided in the kit) to the end of the DNA fragments.
Mixed 5 µl 10x ligation buffer, genomic 0.5 µg, adaptor
(10X) and H2O up to 50 µl, the reaction mixture was
heated to 55°C for 10 min; and then the adaptor
oligonucleotides were allowed to anneal by cooling to
10oC over 1 hour. Then 0.5 µl of T4 DNA ligase was
added, and the reactions incubated at 16°C for 16 hours.
DNA PCR was performed as follows: one denaturation
cycle at 94°C for 5 min, followed by 35 cycles at 94°C
for 1 min, 60°C for 1 min, and 72°C for 50 sec. In the
last cycle, the products were kept at 72°C for an
additional 5 min. One-fifth of each reaction was
separated on a 1.5% agarose gel, stained with ethidium
bromide and photographed. The LM-PCR was
performed using the DNA Ladder Assay (MBI, San
Francisco, CA). 50 μl LM-PCR reactions were prepared
containing 1.0 µg/μl DNA from the diluted
annealing/ligation reaction, and an additional 24 mer at
1.25 pmol/μl, 1× Taq DNA polymerase buffer (67 mM
Tris-HCl pH 8.8, 16.6 mM [NH4]2SO4, 0.45% Triton
X-100, 200μg/ml gelatin, 320 μM dATP, dTTP, dGTP,
dCTP, 2 mM MgCl2 and 0.1 U/μl Taq polymerase as a
Taq-antibody complex allowing a PCR hot-start. The
Taq-antibody complex was prepared with ‘Jumpstart’
Taq antibody (Sigma-Aldrich, MO, USA) according to
instructions, generating a complex at 0.83 (Taq) U/μl.
LM-PCR reactions were heated in a DNA Engine to
94°C for 1 min to activate Taq polymerase and remove
12 mers, then ramped to 72°C for 10 min to re-anneal
the target DNA and generate a complimentary sequence
to the ligated 24 mers. PCR then proceeded over 30
cycles at 94°C for 1 min followed by
annealing/extension at 72°C for 2 min, then completed
with a single 72°C for 10 min extension. 11 µl of each
reaction was electrophoresed on a 2% agarose/EtBr gel.
Proteomics - Western blot analysis
Similar to our recent report ([84]), modiolus/spiral
ganglion neuron tissue lysates were prepared in RIPA
buffer (Pierce #89901, Thermo Scientific, Waltham,
MA) with protease inhibitor cocktail (#78430, Thermo
Scientific, Rockford, IL). Cells and tissue samples were
homogenized in buffer, followed by centrifugation at
2000 X for 10 min at 4oC. Supernatants were loaded at
200 μg of protein/lane, after the protein concentrations
were determined by the Bradford protein assay. Proteins
were fractionated by SDS-PAGE gel electrophoresis
and transferred to a PVDF blotting membrane. The blot
was incubated with β-actin and primary antibodies for
MCR, Bcl-2, Bax and Caspase-8 (Cell Signaling,
Danvers, MA). The secondary antibody was horseradish
peroxidase-conjugated goat anti-rabbit IgG (1:2000,
Cell Signaling).
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Statistical analyses
GraphPad Prism (5.04, La Jolla, CA) was used for data
analyses. One-way analysis of variance (ANOVA) was
used for comparing each group such as young adults vs
middle-aged with treatment and without treatment, for:
BP, serum aldosterone levels, cell density, and genes
and protein expression data. Two-way ANOVA with
repeated measures was used to compare the ABR
threshold shifts in the two middle-aged groups with
treatment durations of 60 and 120 days. Bonferroni
post-hoc tests corrected for multiple comparisons were
used in cases where the ANOVA main effects were
significant. Linear regression was used for measuring
the correlations between ABR threshold shifts and cell
density. The p<0.05 was used for the statistical
significance criterion.
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